Please ensure Javascript is enabled for purposes of website accessibility

FDA Accepts Application for Bristol-Myers Squibb and bluebird bio's Multiple Myeloma CAR-T Therapy

By Todd Campbell – Sep 22, 2020 at 1:20PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Food and Drug Administration's acceptance means it will issue a go/no-go decision on ide-cel in March 2021.

A novel approach to multiple myeloma treatment developed by Bristol-Myers Squibb (BMY -0.39%) and bluebird bio (BLUE 2.31%) took an important step toward commercialization on Tuesday when the Food and Drug Administration announced that it had accepted their application for approval of ide-cel, also known as bb2121.

A chimeric antigen receptor T-cell (CAR-T) therapy, ide-cel elicited a 73% overall response rate in multiple myeloma patients whose disease had returned following a median of three previous treatments.

A person speaks through a megaphone.

IMAGE SOURCE: GETTY IMAGES.

The biotech companies specifically engineered ide-cel to trigger cancer cell death by recognizing and binding to B-cell maturation antigen, or BCMA, a protein expressed predominately by multiple myeloma cells.

In addition to its high overall response rate, 33% of heavily pretreated multiple myeloma patients had a complete response to ide-cel in clinical trials. The median duration of response was 10.7 months and median progression-free survival was 8.8 months. In terms of safety, 84% of patients experienced cytokine release syndrome, or CRS, a potentially life-threatening condition that's common in currently approved CAR-T therapies. Of these cases, 78% were mild or moderate.

An FDA decision on ide-cel is expected on March 27. If the treatment is approved, it will enter a competitive indication. The most widely used multiple myeloma drugs generate billions in revenue annually, including Bristol-Myers' Revlimid, which posted sales of $2.9 billion in the second quarter.

Todd Campbell owns shares of Bluebird Bio and Bristol-Myers Squibb. His clients may have positions in the companies mentioned. The Motley Fool owns shares of and recommends Bluebird Bio and Bristol Myers Squibb. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Bristol Myers Squibb Stock Quote
Bristol Myers Squibb
BMY
$78.83 (-0.39%) $0.30
Bluebird Bio Stock Quote
Bluebird Bio
BLUE
$7.54 (2.31%) $0.17

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
351%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/29/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.